File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: The efficacy and tolerability of risedronate on bone mineral density and bone turnover markers in osteoporotic Chinese women: A randomized placebo-controlled study

TitleThe efficacy and tolerability of risedronate on bone mineral density and bone turnover markers in osteoporotic Chinese women: A randomized placebo-controlled study
Authors
Issue Date2005
PublisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/bone
Citation
Bone, 2005, v. 36 n. 2, p. 358-364 How to Cite?
AbstractOsteoporosis has become an important health problem in postmenopausal Asian populations as the prevalence of hip and vertebral fractures in some Asian countries has risen to approach that of Caucasian populations. Risedronate, a pyridinyl-bisphosphonate agent, is a potent inhibitor of bone resorption. Risedronate increases bone mineral density (BMD), reduces markers of bone turnover, and reduces the risk of fractures in Caucasian postmenopausal women. To determine the efficacy and tolerability of risedronate in Chinese, a multicenter, randomized, double blind, placebo controlled study was performed in Hong Kong. Sixty-five (65) postmenopausal osteoporotic Southern Chinese women, aged 67 ± 6 years, were randomly assigned to receive either risedronate 5 mg daily (n = 31) or placebo (n = 34) for 12 months. All women received calcium carbonate 500 mg daily and vitamin D 400 IU daily. Mean baseline BMD T-score at the spine and total hip was -3.4 and -2.6, respectively. A significant increase in spine BMD was already evident at month 3 of risedronate treatment (P < 0.001). Risedronate significantly increased BMD and reduced bone turnover markers as compared with placebo. The risedronate group had significant increase in BMD at 12 months at both the spine and hip when compared with the placebo group (L1-4 6.6% vs. 0.4%, P < 0.001; total hip 2.7% vs. 0.3, P < 0.0001; femoral neck 1.8% vs. 1.1%, P < 0.02; trochanter 4% vs. 1.1%, P < 0.0001, respectively). Significant changes in urine N-telopeptide (NTx) and serum osteocalcin were evident as early as 1 and 3 months, respectively, with risedronate treatment. No significant changes were seen in both BMD and bone markers in the placebo group. Risedronate was well tolerated without major adverse effects. We conclude that risedronate is an effective and well-tolerated agent for the treatment of postmenopausal osteoporosis in Asian population. © 2004 Elsevier Inc. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/77244
ISSN
2015 Impact Factor: 3.736
2015 SCImago Journal Rankings: 1.752
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLeung, JYYen_HK
dc.contributor.authorHo, AYYen_HK
dc.contributor.authorIp, TPen_HK
dc.contributor.authorLee, Gen_HK
dc.contributor.authorKung, AWCen_HK
dc.date.accessioned2010-09-06T07:29:49Z-
dc.date.available2010-09-06T07:29:49Z-
dc.date.issued2005en_HK
dc.identifier.citationBone, 2005, v. 36 n. 2, p. 358-364en_HK
dc.identifier.issn8756-3282en_HK
dc.identifier.urihttp://hdl.handle.net/10722/77244-
dc.description.abstractOsteoporosis has become an important health problem in postmenopausal Asian populations as the prevalence of hip and vertebral fractures in some Asian countries has risen to approach that of Caucasian populations. Risedronate, a pyridinyl-bisphosphonate agent, is a potent inhibitor of bone resorption. Risedronate increases bone mineral density (BMD), reduces markers of bone turnover, and reduces the risk of fractures in Caucasian postmenopausal women. To determine the efficacy and tolerability of risedronate in Chinese, a multicenter, randomized, double blind, placebo controlled study was performed in Hong Kong. Sixty-five (65) postmenopausal osteoporotic Southern Chinese women, aged 67 ± 6 years, were randomly assigned to receive either risedronate 5 mg daily (n = 31) or placebo (n = 34) for 12 months. All women received calcium carbonate 500 mg daily and vitamin D 400 IU daily. Mean baseline BMD T-score at the spine and total hip was -3.4 and -2.6, respectively. A significant increase in spine BMD was already evident at month 3 of risedronate treatment (P < 0.001). Risedronate significantly increased BMD and reduced bone turnover markers as compared with placebo. The risedronate group had significant increase in BMD at 12 months at both the spine and hip when compared with the placebo group (L1-4 6.6% vs. 0.4%, P < 0.001; total hip 2.7% vs. 0.3, P < 0.0001; femoral neck 1.8% vs. 1.1%, P < 0.02; trochanter 4% vs. 1.1%, P < 0.0001, respectively). Significant changes in urine N-telopeptide (NTx) and serum osteocalcin were evident as early as 1 and 3 months, respectively, with risedronate treatment. No significant changes were seen in both BMD and bone markers in the placebo group. Risedronate was well tolerated without major adverse effects. We conclude that risedronate is an effective and well-tolerated agent for the treatment of postmenopausal osteoporosis in Asian population. © 2004 Elsevier Inc. All rights reserved.en_HK
dc.languageengen_HK
dc.publisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/boneen_HK
dc.relation.ispartofBoneen_HK
dc.rightsBone. Copyright © Elsevier Inc.en_HK
dc.subject.meshAsian Continental Ancestry Groupen_HK
dc.subject.meshBiological Markers - blood - urineen_HK
dc.subject.meshBone Density - drug effects - physiologyen_HK
dc.subject.meshBone Remodeling - drug effects - physiologyen_HK
dc.subject.meshEtidronic Acid - adverse effects - analogs & derivatives - pharmacology - therapeutic useen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHumansen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshOsteoporosis, Postmenopausal - drug therapy - physiopathologyen_HK
dc.titleThe efficacy and tolerability of risedronate on bone mineral density and bone turnover markers in osteoporotic Chinese women: A randomized placebo-controlled studyen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=8756-3282&volume=36&issue=2&spage=358&epage=64&date=2005&atitle=The+efficacy+and+tolerability+of+risedronate+on+bone+mineral+density+and+bone+turnover+markers+in+osteoporotic+Chinese+women:+a+randomized+placebo-controlled+studyen_HK
dc.identifier.emailKung, AWC:awckung@hku.hken_HK
dc.identifier.authorityKung, AWC=rp00368en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.bone.2004.10.014en_HK
dc.identifier.pmid15780963-
dc.identifier.scopuseid_2-s2.0-14144254635en_HK
dc.identifier.hkuros98719en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-14144254635&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume36en_HK
dc.identifier.issue2en_HK
dc.identifier.spage358en_HK
dc.identifier.epage364en_HK
dc.identifier.isiWOS:000227800200020-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridLeung, JYY=36340060100en_HK
dc.identifier.scopusauthoridHo, AYY=7402675209en_HK
dc.identifier.scopusauthoridIp, TP=7003866522en_HK
dc.identifier.scopusauthoridLee, G=36340093800en_HK
dc.identifier.scopusauthoridKung, AWC=7102322339en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats